{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:48:29Z","timestamp":1791478109954,"version":"4.3.4"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The Neonatal Fc Receptor (FcRn) is integral to a wide variety of processes including IgG recycling, serum albumin turnover, and bacterial opsonization. Thus, targeting FcRn will increase antibody degradation including pathogenic IgGs. FcRn inhibition provides a novel therapeutic mechanism by which autoantibody titers are reduced resulting in clinical improvement and disease abatement. The FcRn targeting mechanism is similar to that of intravenous immunoglobulin (IVIg) in which saturated FcRn facilitates accelerated pathogenic IgG degradation. Recently, the FcRn inhibitor efgartigimod was approved for the treatment of myasthenia gravis. Subsequently, clinical trials of this agent have been conducted for numerous inflammatory conditions involving pathogenic autoantibodies. These disorders include the Guillain\u2013Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and inflammatory myositis. Other disorders traditionally treated with IVIg may also benefit from FcRn inhibition in certain contexts. This manuscript discusses the mechanism of FcRn inhibition, preclinical data, and the results of clinical trials of this agent for a wide range of neuromuscular diseases.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000451","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:03:42Z","timestamp":1684854222000},"page":"188-198","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Neonatal Fc Receptor Inhibitor Therapeutics in Neuromuscular Disease"],"prefix":"10.1097","volume":"24","author":[{"given":"Mustafa","family":"Jaffry","sequence":"first","affiliation":[{"name":"Department of Neurology, Rutgers New Jersey Medical School;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Menkes","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oakland University William Beaumont School of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rutgers New Jersey Medical School;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kranthi","family":"Mandava","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rutgers New Jersey Medical School;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0694-3646","authenticated-orcid":false,"given":"Om","family":"Kothari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Drexel University College of Medicine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazim","family":"Jaffry","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rutgers New Jersey Medical School;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Souayah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rutgers New Jersey Medical School;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"R2-20250507","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13311-021-01175-7","article-title":"Neonatal Fc receptor-targeted therapies in neurology","volume":"19","author":"Nelke","year":"2022","journal-title":"Neurotherapeutics"},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/cts.13019","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers","volume":"14","author":"Yap","year":"2021","journal-title":"Clin Translational Sci."},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"175628642199738","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord."},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front Immunol."},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3390\/ijms22063048","article-title":"In translation: FcRn across the therapeutic spectrum","volume":"22","author":"Qi","year":"2021","journal-title":"Int J Mol Sci."},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol."},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/antib9040070","article-title":"Fc engineering strategies to advance IgA antibodies as therapeutic agents","volume":"9","author":"van Tetering","year":"2020","journal-title":"Antibodies (Basel)."},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/282989","article-title":"Pharmacokinetic models for FcRn-mediated IgG disposition","volume":"2012","author":"Xiao","year":"2012","journal-title":"J Biomed Biotechnol."},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest."},{"key":"R13-20250507","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv."},{"key":"R15-20250507","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079","article-title":"RVT-1401, A novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration","volume":"92","author":"Collins","year":"2019","journal-title":"Neurology"},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med."},{"key":"R17-20250507","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"R18-20250507","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol Ther."},{"key":"R19-20250507","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"R20-20250507","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J Immunol."},{"key":"R21-20250507","doi-asserted-by":"crossref","first-page":"892534","DOI":"10.3389\/fimmu.2022.892534","article-title":"Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders","volume":"13","author":"Ward","year":"2022","journal-title":"Front Immunol."},{"key":"R22-20250507","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"R24-20250507","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol."},{"key":"R25-20250507","first-page":"1328","article-title":"The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease","volume":"113","author":"Akilesh","year":"2004","journal-title":"J Clin Invest."},{"key":"R26-20250507","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1073\/pnas.0708960105","article-title":"Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn","volume":"105","author":"Mezo","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R27-20250507","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00109-008-0366-7","article-title":"Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita","volume":"86","author":"Sesarman","year":"2008","journal-title":"J Mol Med (Berl)."},{"key":"R28-20250507","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","article-title":"Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis","volume":"317","author":"Huijbers","year":"2019","journal-title":"Exp Neurol."},{"key":"R29-20250507","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"R30-20250507","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"R31-20250507","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"R32-20250507","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.96.15_supplement.2157","article-title":"Vivacity-MG: a phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of nipocalimab administered to adults with generalized myasthenia gravis","volume":"96","author":"Guptill","year":"2021","journal-title":"Neurology"},{"key":"R35-20250507","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s42466-020-00088-8","article-title":"Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy","volume":"2","author":"Fisse","year":"2020","journal-title":"Neurol Res Pract."},{"issue":"suppl 1","key":"R37-20250507","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2021-eular.1389","article-title":"OP0008\u2005A randomized, double-blind, placebo-controlled phase III trial of IVIG 10% in patients with dermatomyositis. The proderm study: results on efficacy and safety","volume":"80","author":"Aggarwal","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"R38-20250507","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/1744666X.2022.2054803","article-title":"Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev Clin Immunol."},{"key":"R39-20250507","doi-asserted-by":"crossref","first-page":"577387","DOI":"10.1016\/j.jneuroim.2020.577387","article-title":"NMOSD acute attack: understanding, treatment and innovative treatment prospect","volume":"348","author":"Ma","year":"2020","journal-title":"J Neuroimmunol."},{"key":"R40-20250507","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s13311-021-01108-4","article-title":"Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy","volume":"18","author":"Dalakas","year":"2021","journal-title":"Neurotherapeutics"},{"key":"R41-20250507","doi-asserted-by":"crossref","first-page":"e27351","DOI":"10.1097\/MD.0000000000027351","article-title":"Efficacy of therapies in the treatment of Guillain-Barre syndrome: a network meta-analysis","volume":"100","author":"Lin","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R42-20250507","doi-asserted-by":"crossref","first-page":"175628642098674","DOI":"10.1177\/1756286420986747","article-title":"VNTR2\/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis","volume":"14","author":"Su","year":"2021","journal-title":"Ther Adv Neurol Disord."},{"key":"R43-20250507","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/acn3.307","article-title":"Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS","volume":"3","author":"Fokkink","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"R44-20250507","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00401-017-1730-x","article-title":"Modulation of IgG-FcRn interactions to overcome antibody-mediated inhibition of nerve regeneration","volume":"134","author":"Zhang","year":"2017","journal-title":"Acta Neuropathol."},{"key":"R45-20250507","first-page":"e5450","article-title":"Recent advances and therapeutic options in lambert-eaton myasthenic syndrome","volume":"11","author":"Anwar","year":"2019","journal-title":"Cureus"},{"key":"R46-20250507","first-page":"e11995","article-title":"Stiff-person syndrome: a treatment update and new directions","volume":"12","author":"Ortiz","year":"2020","journal-title":"Cureus"},{"key":"R47-20250507","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"R48-20250507","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/CND.0000000000000235","article-title":"Immunoglobulin treatment in neuromuscular medicine","volume":"20","author":"Burakgazi","year":"2019","journal-title":"J Clin Neuromuscul Dis."},{"key":"R49-20250507","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/CPJ.0b013e3182a78ecf","article-title":"Intravenous immunoglobulin for treatment of neuromuscular disease","volume":"3","author":"Ruzhansky","year":"2013","journal-title":"Neurol Clin Pract."},{"key":"R51-20250507","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.98.18_supplement.1531","article-title":"Cost-effectiveness of eculizumab and efgartigimod for the treatment of generalized myasthenia gravis","volume":"98","author":"Lien","year":"2022","journal-title":"Neurology"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:03:01Z","timestamp":1746651781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000451","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}